Skip to content
Toggle main navigation
EndoForum logo
EndoForum logo
  • Join Today
    Log in
    Select an available language
    EN

    Endocrine News

    Endocrine News provides an in-depth look at trends in the field of endocrinology as well as a closer look at recently published research.

    Filter by category
    All
    Adrenal
    Advocacy
    Bone and Mineral
    Cardiometabolic
    Clinical
    COVID-19
    Diabetes
    Diabetes News and Research
    Diabetes Research Articles
    Early Career Corner
    See all

    Results (20)

    FDA Requires Safety Labeling Changes for GLP-1 RAs Due to Potential Increased Risk of Rare But Serious Eye Condition

    FDA Requires Safety Labeling Changes for GLP-1 RAs Due to Potential Increased Risk of Rare But Serious Eye Condition

    Today, the U.S. Food and Drug Administration (FDA) announced that patients and healthcare providers should be aware of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. NAION is a rare condition that can result in acute, painless, decreased vision in one […]The post FDA Requ
    November 9, 2026
    VIDEO: Semaglutide Linked to Lower Bone Fracture Risk

    VIDEO: Semaglutide Linked to Lower Bone Fracture Risk

    [VIDEO]: People taking semaglutide for diabetes had a lower rate of bone fractures compared to those taking other anti-obesity medications, according to research presented at ENDO 2026. Sun Kim, MD, MS, explains the significance of the findings. While these results highlight the potential bone-protective effects of semaglutide, the authors recommend that prospective studies be done […]The post VID
    September 2, 2026
    VIDEO: Clinical Trials Suggest GLP-1s May Improve fertility in Men with Obesity

    VIDEO: Clinical Trials Suggest GLP-1s May Improve fertility in Men with Obesity

    GLP-1s may improve testosterone levels and sperm quality in men with obesity related low testosterone, according to an ENDO 2026 study by Pratibha Natesh, MBBS, MRCP, MRes. Natesh explains the key findings in more detail in our video series.   Scientists at the University Hospitals Coventry and Warwickshire and Warwick Medical School in Coventry, United Kingdom, […]The post VIDEO: Clinical Trials
    August 12, 2026
    New Research Greenlights Popular Obesity Medications for High-Risk Cushing’s Syndrome

    New Research Greenlights Popular Obesity Medications for High-Risk Cushing’s Syndrome

    Popular diabetes and weight-loss medications known as GLP-1 receptor agonists do not increase the risk of cancer in patients with endogenous Cushing’s syndrome, according to a comprehensive nationwide study titled, “GLP-1 Recetor Agonist Exposure and Malignancy Risk in Patients with Endogenous Cushing’s Syndrome,” and published in The Journal of Clinical Endocrinology & Metabolism. The findings […
    August 3, 2026
    VIDEO: Exercise Decreases Among People on GLP-1s

    VIDEO: Exercise Decreases Among People on GLP-1s

    [VIDEO]: People who lost weight with GLP-1 anti-obesity medications tended to log fewer daily steps, according to an analysis of the National Institutes of Health’s All of Us Research Program data. Study lead Sajana Maharjan, MD, of HSHS St. John’s Hospital in Springfield, IL, explains the research she presented at ENDO 2026. GLP-1 receptor agonists […]The post VIDEO: Exercise Decreases Among Peop
    July 28, 2026
    VIDEO: More Than Half of Those Who Stop GLP-1s Restart Within a Year

    VIDEO: More Than Half of Those Who Stop GLP-1s Restart Within a Year

    People who lost weight with GLP-1 anti-obesity medications tended to log fewer daily steps, according to an analysis of the National Institutes of Health’s All of Us Research Program data. Study lead Sajana Maharjan, MD, of HSHS St. John’s Hospital in Springfield, IL, explains the research she presented at ENDO 2026.  “Our study asked two […]The post VIDEO: More Than Half of Those Who Stop GLP-1s
    July 22, 2026
    July 2026 Dashboard

    July 2026 Dashboard

    Highlights from the world of endocrinology 15% The percentage by which fractures decreased when using semaglutide as compared to other weight-loss strategies. Semaglutide also appeared to help the most with weight loss in patients with diabetes. Source: ENDO 2026 presentation by Sun H. Kim, MD, MS, associate professor of medicine in the Division of Endocrinology, […]The post July 2026 Dashboard ap
    July 21, 2026
    Moving Forward: The Future of GLP-1 Therapies

    Moving Forward: The Future of GLP-1 Therapies

    The Endocrine Society recently held a virtual Science Writers Conference dedicated to the current landscape and future horizons of GLP-1 therapies, examining new oral formulations and dual and triple agonists. Endocrine News caught up with the two experts who spoke at the conference — Priya Jaisinghani, MD, DABOM and Mehmet Furkan Burak, MD – to learn what’s next for these medications and what the
    March 11, 2026
    No Patient Left Behind: Expanding Semaglutide’s Reach

    No Patient Left Behind: Expanding Semaglutide’s Reach

    Recent studies from Endocrine Society journals have shown that GLP-1 RAs are not only successful in reducing obesity, but they have positive impacts on a range of other conditions. From improving taste sensitivity and positive results in a pediatric patient with several comorbidities to being an effective treatment in patients with a variety of psychiatric disorders, these drugs are routinely exce
    March 9, 2026
    Side Effects: Endocrine Society Journals Look at GLP-1RAs and the Positive and Negative Unintended Impacts

    Side Effects: Endocrine Society Journals Look at GLP-1RAs and the Positive and Negative Unintended Impacts

    As the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) expands, so too does our knowledge of just what all these medications can do. GLP-1RAs have now been shown to reduce consumption of alcohol and drugs, even treating addictions to gambling and sex, but these medications can also potentially lead to rare but fatal complications of which endocrinologists should be aware.Glucagon-like
    February 19, 2026
    Compare and Contrast: As Glucagon-Like Peptide-1 Receptor Agonist Access Expands, Comparative Heart Outcomes Matter

    Compare and Contrast: As Glucagon-Like Peptide-1 Receptor Agonist Access Expands, Comparative Heart Outcomes Matter

    As the onslaught of anti-obesity drugs hit the market in recent years, more research is being released about their potential side effects as well as their benefits. Endocrine News investigates two of these studies to gain more insight to how these “miracle drugs” could affect cardiac health.At a GlanceAmong patients with type 2 diabetes and atherosclerotic CVD, the dual agonist tirzepatide was non
    February 17, 2026
    Beyond the Scale: What Else Glucagon-like Peptide-1 Receptor Agonists Can Do

    Beyond the Scale: What Else Glucagon-like Peptide-1 Receptor Agonists Can Do

    In the United States, American Hearth Month is observed in February to raise awareness about cardiovascular disease, the leading cause of death worldwide. To a similar end, Endocrine News focuses on a few recent journal studies that take a closer look at the impacts of incretin-based therapies in the setting of obesity and impaired cardiovascular health, as well as how they affect the liver, quali
    February 13, 2026
    New Research Challenges Fears of Semaglutide-Linked Thyroid Cancer Risk

    New Research Challenges Fears of Semaglutide-Linked Thyroid Cancer Risk

    The “black box” warning on the popular diabetes and weight loss drug semaglutide may be shifting from a cautionary black to a reassuring grey. A landmark study published in The Journal of Clinical Endocrinology & Metabolism reveals that semaglutide does not promote thyroid cancer; instead, it may suppress tumor growth by “reprogramming” the immune system to fight it.Thyroid cancer is the most comm
    February 12, 2026
    Lilly’s Oral GLP-1 Orforglipron Demonstrates Superiority in Phase 3 Diabetes Trials

    Lilly’s Oral GLP-1 Orforglipron Demonstrates Superiority in Phase 3 Diabetes Trials

    Eli Lilly’s “Ozempic-in-a-pill” candidate just cleared its most significant clinical hurdle to date. The pharmaceutical giant announced that its experimental once-daily pill, orforglipron, met all primary and secondary endpoints in two pivotal Phase 3 trials: ACHIEVE-2 and ACHIEVE-5. Data indicate that this oral treatment provides superior glycemic control compared to both a standard SGLT-2 inhibi
    February 11, 2026
    Novo Nordisk’s OASIS 4 Study Validates Daily Oral Pill for Chronic Weight Management

    Novo Nordisk’s OASIS 4 Study Validates Daily Oral Pill for Chronic Weight Management

    A new year brings a new therapeutic milestone for weight management: Following its recent U.S. Food and Drug Administration approval, the 25 mg oral semaglutide tablet (brand name: Wegovy), a once-daily pill became available in the United States in early January 2026 for chronic weight management and for reducing the risk of major adverse cardiovascular events in adults living with obesity or over
    February 10, 2026
    New Study Links Combination of Hormone Therapy and Tirzepatide to Greater Weight Loss after Menopause

    New Study Links Combination of Hormone Therapy and Tirzepatide to Greater Weight Loss after Menopause

    A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide. The findings, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, could expand treatment possibilities for millions of women struggling with obesity and obesity-related diseases after menopause.Menopause can accelerate age-related weight
    January 29, 2026
    EUREKA! The Top Endocrine Science of 2025

    EUREKA! The Top Endocrine Science of 2025

    For the eleventh year running, Endocrine News talks to editors from Endocrine Society publications to unearth the most impressive breakthroughs in endocrine science and research for 2025. From GLP-1s, adrenal treatments, and acromegaly breakthroughs to obesity, diabetes, and cutting-edge research in reproductive medicine, 2025 was a banner year for endocrine research and researchers!For more than
    December 11, 2025
    Tirzepatide Improves Blood Sugar Control in Children Aged 10-17 Years with Type 2 Diabetes

    Tirzepatide Improves Blood Sugar Control in Children Aged 10-17 Years with Type 2 Diabetes

    New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both.The study (the SURPASS-PEDS trial), led by Tamara Hannon,
    December 2, 2025
    As GLP-1 Prescriptions Soar, Poison Center Study Finds Exposures Are Common But Generally Mild

    As GLP-1 Prescriptions Soar, Poison Center Study Finds Exposures Are Common But Generally Mild

    A new study from a poison control center in Alabama offers a reassuring perspective on the rising number of calls related to popular GLP-1 receptor agonists, such as Ozempic and Wegovy. While exposures to these medications have increased significantly over the past two decades, the research suggests many cases are accidental, associated with mild symptoms, and rarely lead to serious health complic
    October 10, 2025
    GLP-1s Show Promise in Treating Alcohol and Drug Addiction

    GLP-1s Show Promise in Treating Alcohol and Drug Addiction

    A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug addiction, according to a new paper published in the Journal of the Endocrine Society.The therapies, known as Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs), present an encouraging approach to treating alcohol and other substance use disorders.“Early research in both animals a
    October 9, 2025
    Contact
    1 (888) 363-6762
    Cookies
    Reselect cookie settings
    Community engagement platform by Hivebrite.